Iptacopan (LNP023)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Trial Timeline
Jul 19, 2021 → Apr 18, 2023
NCT ID
NCT04820530About Iptacopan (LNP023)
Iptacopan (LNP023) is a phase 3 stage product being developed by Novartis for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is completed. This product is registered under clinical trial identifier NCT04820530. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH).
What happened to similar drugs?
0 of 20 similar drugs in Paroxysmal Nocturnal Hemoglobinuria (PNH) were approved
Approved (0) Terminated (4) Active (16)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04820530 | Phase 3 | Completed |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 36 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Ravulizumab | AstraZeneca | Pre-clinical | 30 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Danicopan | AstraZeneca | Phase 3 | 47 |
| LNP023 | Novartis | Pre-clinical | 33 |
| iptacopan | Novartis | Phase 2 | 35 |
| LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Pre-clinical | 30 |
| Iptacopan | Novartis | Phase 3 | 40 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 40 |
| LNP023 | Novartis | Phase 3 | 47 |
| LFG316 + LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Crovalimab | Roche | Phase 3 | 44 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 40 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 33 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 27 |
| Humanized anti-Factor Bb monoclonal antibody + Placebo | Sanofi | Phase 1 | 29 |